The results showed that YWDHNNPQIR could inhibit DN renal fibrosis by inhibiting the MAPK and NF-κB pathways, and it is expected to be designed as a natural drug for treating DN renal fibrosis. Here, NFKB1 is linked to renal fibrosis.